Twenty-two patients with recurrent or metastatic squamous cell carcinoma of the head and neck were treated with piroxantrone 150 mg/m2 intravenously every 21 days. There were no objective responses. The 95% upper confidence bound for response is 15%. Primary toxicity was hematologic.

Aged↗

PubMedDate not supplied

Phase I study of pyrazofurin and 5-azacytidine in refractory adult acute leukemia.

Twenty-eight patients with refractory adult acute leukemia were treated with pyrazofurin and 5-azacytidine. Seven patients showed a response. Dermatitis and mucositis were severe at doses of pyrazofurin greater than 50 mg/m2/day and precluded administration of multiple courses in most patients. As a result of this toxicity, 16 patients received only one course of chemotherapy. The response rates achieved with this combination were not superior to those achieved with 5-azacytidine alone.

Amides↗

PubMedDate not supplied

Phase II study of hexamethylmelamine in refractory Hodgkin's disease, other lymphomas, and chronic lymphocytic leukemia.

A long-term daily dose of hexamethylmelamine was tested in patients with Hodgkin's disease, nodular and diffuse lymphomas, and chronic lymphocytic leukemia who had failed conventional treatment. There were no responses among 20 patients with chronic lymphocytic leukemia, 12 with nodular lymphomas, and 11 with diffuse well-differentiated lymphocytic lymphomas. However, five of 24 patients with Hodgkin's disease (21%) responded and seven of 36 (19%) with diffuse lymphomas other than diffuse well-differentiated lymphocytic lymphomas responded. This new agent is active in selected histologic types of lymphoma.

Adult↗